• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
-
Generic Name: glucagon infusion
Date Designated: 09/25/2014
Orphan Designation: Prevention of chronic, severe hypoglycemia related to congential hyperinsulinism
Orphan Designation Status: Designated
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
Xeris Pharmaceuticals, Inc.
1375 West Fulton Street, Suite 1300
Chicago, Illinois 60607
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-